EVOK — Evoke Pharma Balance Sheet
0.000.00%
- $3.85m
- -$4.75m
- $10.25m
Annual balance sheet for Evoke Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 8.07 | 9.14 | 9.84 | 4.74 | 13.6 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.023 | 0.295 | 0.625 | 0.673 | 2.42 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9.28 | 10.6 | 11.7 | 6.83 | 17.2 |
Net Property, Plant And Equipment | 0.142 | 0.012 | 0.129 | 0 | 0.154 |
Other Long Term Assets | |||||
Total Assets | 9.43 | 10.6 | 11.9 | 7.07 | 17.5 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7.54 | 1.41 | 1.65 | 3.04 | 10.4 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 12.6 | 7.02 | 7.77 | 9.65 | 10.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -3.21 | 3.56 | 4.08 | -2.58 | 7.04 |
Total Liabilities & Shareholders' Equity | 9.43 | 10.6 | 11.9 | 7.07 | 17.5 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |